Skip to main content
Combined Biomarker and Drug Development
28, Feb 2013

Combined Biomarker and Drug Development-A range of antigen-specific and non-specific cell-based assays

We were recently asked by one of our customers if our products could serve as a platform to develop companion diagnostics during drug testing.

Plexision performs custom R and D projects aimed at integrating biomarker targets in all phases of drug development, from preclinical to post-marketing.

A range of antigen-specific and non-specific cell-based assays can be adapted for immunological drug development services in the following categories:

  • Predicting effective concentrations of single and multiple-drug regimens.
  • Design and development of cell-based companion diagnostics.
  • Surrogate endpoint development.
  • Assay validation and performance assessment.

Plexision can also assist drug developers in regulatory submissions for biomarker qualification.

If you would like to know more about our research capabilities, please contact us at drugs@plexision.com.

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact